Roche was in 'advanced' talks to out-license its Angelman syndrome drug, but potential partner withdrew
Roche is back to square one for finding a partner to carry forward its culled Angelman syndrome drug.
Last June, the Swiss pharma had started …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
